GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (STU:ECX) » Definitions » Cyclically Adjusted PS Ratio

Epigenomics AG (STU:ECX) Cyclically Adjusted PS Ratio : 0.12 (As of May. 26, 2024)


View and export this data going back to . Start your Free Trial

What is Epigenomics AG Cyclically Adjusted PS Ratio?

As of today (2024-05-26), Epigenomics AG's current share price is €1.59. Epigenomics AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2023 was €13.48. Epigenomics AG's Cyclically Adjusted PS Ratio for today is 0.12.

The historical rank and industry rank for Epigenomics AG's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:ECX' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.11   Med: 2.96   Max: 35.99
Current: 0.12

During the past years, Epigenomics AG's highest Cyclically Adjusted PS Ratio was 35.99. The lowest was 0.11. And the median was 2.96.

STU:ECX's Cyclically Adjusted PS Ratio is ranked better than
94.78% of 134 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.38 vs STU:ECX: 0.12

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Epigenomics AG's adjusted revenue per share data for the three months ended in Jun. 2023 was €0.082. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €13.48 for the trailing ten years ended in Jun. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Epigenomics AG Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Epigenomics AG's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigenomics AG Cyclically Adjusted PS Ratio Chart

Epigenomics AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.18 13.00 4.20 0.93 0.60

Epigenomics AG Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 0.45 0.60 0.22 0.30

Competitive Comparison of Epigenomics AG's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, Epigenomics AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Epigenomics AG's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Epigenomics AG's Cyclically Adjusted PS Ratio falls into.



Epigenomics AG Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Epigenomics AG's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.59/13.48
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Epigenomics AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2023 is calculated as:

For example, Epigenomics AG's adjusted Revenue per Share data for the three months ended in Jun. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=0.082/123.1404*123.1404
=0.082

Current CPI (Jun. 2023) = 123.1404.

Epigenomics AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201309 3.023 98.983 3.761
201312 6.742 99.356 8.356
201403 4.196 99.543 5.191
201406 4.309 99.543 5.331
201409 3.021 99.823 3.727
201412 4.162 99.543 5.149
201503 3.398 99.717 4.196
201506 4.127 100.417 5.061
201509 3.798 100.417 4.657
201512 6.016 99.717 7.429
201603 2.269 100.017 2.794
201606 9.065 100.717 11.083
201609 6.042 101.017 7.365
201612 11.795 101.217 14.350
201703 1.713 101.417 2.080
201706 1.557 102.117 1.878
201709 2.149 102.717 2.576
201712 5.657 102.617 6.788
201803 1.968 102.917 2.355
201806 2.943 104.017 3.484
201809 3.465 104.718 4.075
201812 1.023 104.217 1.209
201903 1.199 104.217 1.417
201906 1.481 105.718 1.725
201909 0.734 106.018 0.853
201912 1.069 105.818 1.244
202003 0.866 105.718 1.009
202006 0.277 106.618 0.320
202009 0.742 105.818 0.863
202012 1.003 105.518 1.171
202103 0.359 107.518 0.411
202106 0.210 108.486 0.238
202109 6.494 109.435 7.307
202112 0.233 110.384 0.260
202203 0.144 113.968 0.156
202206 0.154 115.760 0.164
202209 0.177 118.818 0.183
202212 0.121 119.345 0.125
202303 0.157 122.402 0.158
202306 0.082 123.140 0.082

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Epigenomics AG  (STU:ECX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Epigenomics AG Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Epigenomics AG (STU:ECX) Business Description

Traded in Other Exchanges
Address
Geneststrasse 5, Berlin, BB, DEU, 10829
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.